Reduced/No Dexamethasone With Netupitant/Palonosetron and Olanzapine for Chemotherapy‑Induced Nausea/Vomiting in Highly Emetogenic Chemotherapy: Phase III Noninferiority Trial.

In 30 seconds

This phase III randomized controlled trial evaluated the efficacy of netupitant/palonosetron plus olanzapine with reduced or no dexamethasone in preventing chemotherapy-induced nausea and vomiting in patients undergoing highly emetogenic chemotherapy. Among 644 patients, complete response rates were 72.4% for standard dexamethasone, 72.2% for the dexamethasone-sparing regimen, and 70.1% for the dexamethasone-free regimen, demonstrating noninferiority.

Key findings

• Complete response rates were 72.4% for standard DEX and 72.2% for DEX-sparing, meeting noninferiority criteria.
• The DEX-free regimen achieved a complete response rate of 70.1%, also confirming noninferiority.
• Steroid-related toxicities were significantly lower in the DEX-sparing and DEX-free groups compared to standard DEX.

Why it matters

Reducing or omitting dexamethasone in chemotherapy regimens may lower toxicity and improve patient quality of life, particularly in the context of immunotherapy, where steroid use can interfere with treatment efficacy.